| Net income | |
| Change in fair value of common stock warrants | |
| Depreciation, depletion and amortization | 29.1M |
| Accretion expense | 600K |
| Amortization of finance fees | 1.2M |
| Stock-based compensation | |
| Product inventory write-down | |
| Deferred income tax benefit | 200K |
| Unrealized loss (gain) on derivative instruments | 1.2M |
| Change in working capital accounts (Note 13) | -2.3M |
| Cash generated by operating activities | 6.3M |
| Short-term investments | |
| Capital expenditures | |
| Restricted cash | -3.1M |
| Reclamation deposit | |
| Cash generated (used) by investing activities | -19.3M |
| Proceeds from issuance of common shares, net | 0 |
| Proceeds from senior unsecured note issuance, net (Note 7) | |
| Debt issuance costs | |
| Repayment of long-term debt | 0 |
| Cash generated (used) by financing activities | -6.5M |
| EFFECT OF EXCHANGE RATE CHANGES ON CASH | |
| INCREASE IN CASH AND CASH EQUIVALENTS | |
| Cash and cash equivalents, beginning of period | 139.1M |
| Cash and cash equivalents, end of period | 119.7M |